The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the “Company”) today […]
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the “Company”) today […]
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the “Company”) today […]
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the “Company”) today […]
HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house developed next-generation balloon-expandable dry-tissue transcatheter […]
